Skip to content

Bin Deng

4 papers in the library · 6 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Ketamine improves ovarian function and oocyte quality in CORT-induced depression mouse model by ferroptosis pathway

Cell Death Discovery August 8, 2026 Yuqing Liu, Jiang Jiang, Yalong Wang et al.

Depression is a common psychiatric disorder, with a higher prevalence in women than in men, and has been increasingly associated with disturbances in female reproductive health. In particular, depressive conditions may impair ovarian function and compromise oocyte quality, thereby contributing to reproductive disorders. Ketamine is a clinically effective antidepressant. However, its potential...

Intranasal Ketamine Alleviates Depressive-like Behaviors in Chronic Unpredictable Mild Stress Rats in Association with Hypothalamic NADH:Ubiquinone Oxidoreductase Subunit A10.

European Journal of Pharmacology July 19, 2026 Yongning Lv, Zihe Yang, Linjie Li et al.

Intranasal ketamine represents a rapid and minimally invasive antidepressant strategy, yet the molecular mechanisms underlying its antidepressant-like effects after intranasal administration remain incompletely understood. Male Sprague-Dawley rats were subjected to a 28-day chronic unpredictable mild stress (CUMS) paradigm and then received intranasal racemic ketamine at 8.58 mg/kg twice weekly...

Pharmacokinetics and brain distribution of ketamine after nasal administration.

Journal of Pharmaceutical and Biomedical Analysis October 15, 2025 Zihe Yang, Linjie Li, Bin Deng et al. 3 citations

Major depressive disorder is a severe mental condition characterized by abnormalities in the structure and function of the brain. Ketamine is a novel antidepressant that has rapid effects on depression. This drug is clinically used to treat depression in patients with acute suicidal ideation or behavior. It is typically administered at a dose of 84 mg. However, the distribution of ketamine in...

The post-marketing safety of Esketamine among older adults(≥ 65): an real-world pharmacovigilance study.

BMC pharmacology & toxicology August 29, 2025 Bin Deng, Zhiwen Fu, Linjie Li et al. 3 citations

AIMS: This study aims to investigate the safety profile of Esketamine, with a particular focus on comparing adverse events (AEs) between adults (< 65 years) and older adults (≥ 65 years) using data from the FDA Adverse Event Reporting System (FAERS). METHODS: We conducted a comprehensive analysis of FAERS data from 2019 to 2024, identifying 6,452 Esketamine-related AE reports. After removing...